Table 4. Outcome of NSCLC patients treated with gefitinib according to the combined status of EGFR FISH and HER3 FISH.
| Markers | Total | OR (%) | SD+PD (%) | DCR (%) | PD (%) | TTP (months) | OS (months) |
|---|---|---|---|---|---|---|---|
| EGFR+/HER3+a | 11 | 4 (36.4) | 7 (63.6) | 7 (63.6) | 4 (36.4) | 7.7 | 13.8 |
| EGFR+and/or HER3+b | 39 | 9 (23.1) | 30 (76.9) | 20 (51.3) | 19 (48.7) | 5.9 | 13.8 |
| EGFR+/HER3−c | 17 | 5 (29.4) | 12 (70.6) | 10 (58.8) | 7 (41.2) | 9 | 18.7 |
| EGFR− and/or HER3−d | 71 | 7 (9.9) | 64 (90.1) | 24 (33.8) | 47 (66.2) | 2.7 | 10.1 |
| EGFR−/HER3+e | 11 | 0 | 11 (100) | 3 (27.3) | 8 (72.7) | 2.7 | 7.3 |
| EGFR−/HER3−f | 43 | 2 (4.7) | 41 (95.3) | 11 (25.6) | 32 (74.4) | 2.6 | 8.5 |
| P (avsc) | 1 | 1 | 0.32 | 0.85 | |||
| P (avsd) | 0.037* | 0.09 | 0.032* | 0.27 | |||
| P(avse) | 0.09 | 0.19 | 0.32 | 0.24 | |||
| P (bvsf) | 0.014* | 0.017* | 0.002* | 0.25 | |||
*
Statistically significant.
a
Groups compared statistically significant.
b
Groups compared statistically significant.
c
Groups compared statistically significant.
d
Groups compared statistically significant.
e
Groups compared statistically significant.
f
Groups compared statistically significant.